ATP citrate-lyase

CAT # Inoa Huahana wehewehe
CPD3611 SB-204990 ʻO SB-204990 ka prodrug o ka potent ATP citrate-lyase inhibitor SB-201076. ʻO SB-204990, i ka wā i hāʻawi ʻia ai i ka waha i nā ʻiole, ua komo i loko o ka ʻōnaehana systemic, ua hoʻihoʻi ʻia nā manaʻo pharmacologically pili o SB-201076 i loko o ke ake. ʻO SB-204990 (25 mg/kg i kēlā lā i kēia lā) ua hoʻemi pū i nā pae cholesterol plasma (a hiki i ka 23%) a me nā pae triglyceride (a hiki i 38%) i ka ʻīlio, ʻoi aku ka maikaʻi e hoʻemi i ka lipoprotein haʻahaʻa haʻahaʻa i hoʻohālikelike ʻia me ka lipoprotein cholesterol kiʻekiʻe. pae. He enzyme koʻikoʻi ka SB-204990 i ka hoʻomalu ʻana i ka lako substrate no ka lipid synthesis de novo a me kahi pahuhopu enzyme kūpono no ka hana hypolipidaemic.
,

Kāhea iā mā˚ou

Ninau

Nuhou Hou

  • ʻO 7 ʻoi loa ma ka noiʻi lāʻau lapaʻau ma 2018

    ʻO 7 ʻoi loa i ka noiʻi lāʻau lapaʻau I...

    Ma lalo o ka piʻi nui ʻana o ka hoʻokūkū e hoʻokūkū i kahi ʻenehana paʻakikī a me ka ʻenehana, pono e hoʻomau nā ʻoihana lāʻau lapaʻau a me biotech i kā lākou papahana R&D e noho i mua ...

  • ARS-1620: He mea hoʻohiki hou no nā maʻi maʻi KRAS-mutant

    ARS-1620: He mea hoʻohiki hou no K...

    Wahi a kahi noiʻi i paʻi ʻia ma Cell, ua hoʻomohala nā mea noiʻi i kahi inhibitor kūikawā no KRASG12C i kapa ʻia ʻo ARS-1602 i hoʻoulu i ka regression tumor i nā ʻiole. "Ke hāʻawi nei kēia haʻawina i nā hōʻike vivo e hiki ke lilo i mutant KRAS ...

  • Loaʻa iā AstraZeneca ka hoʻoikaika kānāwai no nā lāʻau lapaʻau oncology

    Loaʻa iā AstraZeneca ka hoʻonui hoʻoponopono no...

    Ua loaʻa iā AstraZeneca kahi hoʻonui pālua no kāna kōpili oncology i ka Pōʻalua, ma hope o ka ʻae ʻana o nā regulators US a me ʻEulopa i nā hoʻouna kānāwai no kāna mau lāʻau lapaʻau, ʻo ka hana mua i ka lanakila ʻana i kēia mau lāʻau lapaʻau. ...

WhatsApp kamaʻilio pūnaewele!